Meeting
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
Authors
Charles Geyer
NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA
Charles Geyer , Aditya Bardia , Nadia Harbeck , Mothaffar F. Rimawi , Sara A. Hurvitz , Miguel Martin , Sherene Loi , Shigehira Saji , Kyung Hae Jung , Gustavo Werutsky , Daniil Stroyakovskiy , Vanesa López-Valverde , Michael Davis , Tanja Badovinac Crnjevic , Pablo Diego Pérez-Moreno , Peter Schmid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04961996
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS616)
DOI
10.1200/JCO.2023.41.16_suppl.TPS616
Abstract #
TPS616
Poster Bd #
445b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
First Author: Seock-Ah Im
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
First Author: William John Gradishar